Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$10.45 +4.0%	$6.00	$3.35 ▼ $20.30	$281.82M	1.04	253,879 shs	155,702 shs
DBVT DBV Technologies	$9.58 +0.8%	$9.80	$2.20 ▼ $12.78	$260.32M	-0.58	35,644 shs	21,453 shs
GALT Galectin Therapeutics	$4.28 +0.7%	$3.16	$0.73 ▼ $4.41	$274.18M	0.82	245,112 shs	176,201 shs
ZIVO ZIVO Bioscience	$17.01	$14.48	$9.97 ▼ $22.15	$64.93M	-0.06	1,069 shs	50 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+3.98%	+5.13%	+73.88%	+188.67%	-43.45%
DBVT DBV Technologies	+1.48%	-4.20%	+1.91%	+15.42%	+120.23%
GALT Galectin Therapeutics	+0.71%	+4.39%	+18.89%	+226.72%	+49.65%
ZIVO ZIVO Bioscience	0.00%	-5.50%	+58.97%	-9.13%	+57.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.1212 of 5 stars	3.6	5.0	2.7	0.8	0.6
DBVT DBV Technologies	3.3286 of 5 stars	3.4	5.0	2.5	2.5	0.6
GALT Galectin Therapeutics	2.2393 of 5 stars	3.5	0.0	3.5	3.3	0.0
ZIVO ZIVO Bioscience	0.2024 of 5 stars	0.0	3.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.75	117.70% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	53.97% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	40.19% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, CTNM, DBVT, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
8/14/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	5.86	N/A	N/A	$6.11 per share	1.71
DBVT DBV Technologies	$4.15M	63.23	N/A	N/A	$3.15 per share	3.04
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.86) per share	N/A
ZIVO ZIVO Bioscience	$15.85K	4,096.35	N/A	N/A	($0.81) per share	-21.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.64	N/A	N/A	N/A	N/A	N/A	-225.32%	11/13/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$2.58	N/A	∞	N/A	N/A	N/A	-2,240.92%	11/12/2025 (Estimated)

Latest ZIVO, CTNM, DBVT, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	-$0.12	+$0.04	-$0.12	N/A	N/A
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	24.51	24.51
DBVT DBV Technologies	N/A	2.45	2.45
GALT Galectin Therapeutics	N/A	1.43	1.43
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
DBVT DBV Technologies	71.74%
GALT Galectin Therapeutics	11.68%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
DBVT DBV Technologies	1.44%
GALT Galectin Therapeutics	50.10%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
GALT Galectin Therapeutics	9	64.06 million	31.97 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

ZIVO, CTNM, DBVT, and GALT Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Passes Above 50 Day Moving Average - Here's Why

August 30 at 4:51 AM | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) versus Cortexyme (NASDAQ:CRTX) Head-To-Head Comparison

August 26, 2025 | americanbankingnews.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

August 22, 2025 | marketbeat.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, CTNM, DBVT, and GALT Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$10.45 +0.40 (+3.98%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$10.48 +0.03 (+0.24%)

As of 08/29/2025 06:29 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

DBV Technologies NASDAQ:DBVT

$9.58 +0.08 (+0.84%)

Closing price 08/29/2025 03:58 PM Eastern

Extended Trading

$9.58 0.00 (0.00%)

As of 08/29/2025 06:24 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Galectin Therapeutics NASDAQ:GALT

$4.28 +0.03 (+0.71%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$4.26 -0.02 (-0.49%)

As of 08/29/2025 07:56 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

ZIVO Bioscience NASDAQ:ZIVO

$17.01 0.00 (0.00%)

As of 08/29/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time